retatrutide triple agonist gip glp-1 glucagon receptor Retatrutide—A Game Changer in Obesity Pharmacotherapy Dual and Triple Gut Peptide

Book an appointment with Passion Health Advanced Primary Care today

The drug appears to work harder when there is more metabolic dysfunction to correct

mTORC1 is active in stem cells located at the base of intestinal crypts but silenced as transit-amplifying cells differentiate into enterocytes or secretory cells along the epithelium

Specify the medication name, dosage, and frequency

For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com

Cardiovascular benefits have been demonstrated in clinical trials for specific GLP-1 receptor agonists, with liraglutide, semaglutide, and dulaglutide showing reductions in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk